CASE REPORT

Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report

Bushra Tbakhi1 | Fateeha Furqan2 | Glynis Scott3 | Jane L. Liesveld1 | Omar S. Aljitawi1

1 Department of Hematology and Oncology, University of Rochester, Rochester, New York (Email: jane_liesveld@urmc.rochester.edu; omar_aljitawi@urmc.rochester.edu)
2 Department of Internal Medicine, Rochester General Hospital, Rochester, New York
3 Department of Dermatology and Pathology, University of Rochester, Rochester, New York

Correspondence
Bushra Tbakhi, Department of Hematology and Oncology, University of Rochester, 601 Elmwood Ave, Rochester, NY 14623. Email: bushra_tbakhi@urmc.rochester.edu

Funding information
National Institutes of Health (NIH), Grant/Award Number: R37CA225791

Abstract
Neutrophil recovery after autologous hematopoietic cell transplantation (ASCT) is affirmed with achievement of an absolute neutrophil count (ANC) of ≥500/µL. There is growing evidence that neutrophils may be observed despite undetectable peripheral ANC counts following autologous hematopoietic cell transplant and are preferentially delivered to sites of inflammation. We report an interesting case that confirms neutrophil tissue delivery to the skin two days prior to evidence of blood engraftment after an ASCT.

KEYWORDS
ANC, autologous, engraftment, neutrophil, skin

1 | INTRODUCTION
Myeloid engraftment is defined as an absolute neutrophil count (ANC) of ≥500/µL and is often achieved within 14 days of transplant [1,2]. Potential methods of earlier identification of marrow recovery have been explored, although their clinical use is not yet widespread. We report a compelling case that demonstrates neutrophil tissue delivery, confirmed by skin biopsy, two days prior to evidence of blood engraftment in a patient who received an autologous hematopoietic stem cell transplantation (ASCT).

2 | CASE REPORT
A 54-year-old man diagnosed with multiple myeloma received induction therapy with dexamethasone, bortezomib and cyclophosphamide, which was later changed to lenalidomide, bortezomib, and dexamethasone. After completing four cycles of chemotherapy with minimal side effects, he was referred for treatment with high-dose chemotherapy followed by autologous stem cell rescue. He completed peripheral blood stem cell mobilization and harvest and received myeloablative conditioning with melphalan 200 mg/m² on day −1. He was also enrolled into the hyperbaric oxygen (HBO) clinical trial (registered with Clinicaltrials.gov, number NCT03398200), which aims to investigate the effect of using HBO on the duration to neutrophil recovery after transplant and was randomized into the HBO cohort group. The patient underwent HBO therapy 6 h prior to his ASCT on Day 0, and then received the complete stem cell dose of 2.45 × 10⁶ CD34+ cells without any immediate complications. However, 8 days after transplant, he developed fevers and rigors. Blood work revealed leukopenia with zero ANC. Infectious work up for his febrile neutropenia including blood cultures was obtained and he was started on empiric intravenous cefepime and metronidazole. Electrolytes were normal including a phosphorus of 3.4 mg/dL. On day 10 post auto-HSCT, the patient developed an erythematous, tender swelling with induration on the left flank, without any history of preceding trauma (see Figure 1). Blood work still indicated an ANC of zero, absolute monocyte count of 100/µL and a phosphorus level of 1.6 mg/dL. Infectious disease service...
was consulted, and empiric vancomycin was added. However, the
swelling continued to increase and developed discoloration prompting
a dermatology consultation and a punch biopsy (Day +10). Both the
gram stain and culture remained negative for bacterial growth, but
the biopsy results revealed necrosis of the subcutis and mixed sparse
dermal infiltrate of lymphocytes and neutrophils and some eosinophils
as well as subepidermal edema.

On day 12 post ASCT, the patient achieved hematologic recovery
with an ANC of 200/µL, and the phosphorus levels reached a nadir
of 1.2 mg/dL. His fevers and cellulitis improved. He was discharged
on the 14th day posttransplant with oral moxifloxacin as well as topi-
cal mupirocin. The patient was seen as outpatient with improvement
in the cellulitis and no further febrile episodes.
DISCUSSION

Our case illustrates that neutrophil tissue delivery was indeed present prior to myeloid engraftment as his ANC was zero on the day of the biopsy of the skin lesion that demonstrated neutrophils in the tissue. Detection of ANC in this way is clearly not a replicable method of predicting early engraftment but does support the existing notion that marrow recovery occurs prior to the rising of an ANC level.

This incident also demonstrates that neutrophils mobilized to the site of inflammation, similar to the early delivery of neutrophils to the oral cavity. The presence of salivary neutrophils is in response to mucositis, a side effect of chemotherapy, which constitutes a common site of injury in this particular patient population [3]. However, there is evidence to support the rise of oral neutrophils in addition to blood neutrophils occurs by merit of inflammatory states not necessarily involving the oral cavity [4]. Of note, this patient was involved in the HBO clinical trial and was randomized to the interventional group, which may have affected the time to neutrophil recovery [5].

A variety of predictors of marrow recovery indicate that engraftment likely occurs earlier than the conventional evidence of an ANC level \( \geq 500/\mu L \). Examples of these markers include detection of neutrophils in oral mucosa, early monocyte recovery, hypophosphatemia, and measuring the immature reticulocyte population [6–9]. Their use has suggested that marrow recovery after HSCT likely occurs at least 2 days earlier than blood engraftment. Oral rinses have been shown to detect neutrophils at a range of 2–8 days earlier than neutrophils in the circulation [6,10,11]. While this is a noninvasive method, their collection may be limited by presence of oral mucositis and nausea [11]. Absolute monocyte count \( \geq 100/\mu L \) has been suggested to antedate ANC by about 5 days [7,12]. The use of blood cell parameters (including volume, conductivity, and light scatter) showed earlier engraftment by approximately 4 days in both autologous and allogenic transplant groups, with the only difference between them being related to the volume of stem cells infused [12]. Hypophosphatemia (a drop in levels by 20%) is an electrolyte that can also reflect marrow recovery due to cell replication, although this is nonspecific and can be influenced by iatrogenic supplementation [7,9]. In this particular case, hypophosphatemia, specifically a drop of 47% from baseline occurred congruently with the evidence of tissue neutrophil delivery, monocyte recovery, and prior to ANC recovery. Immature reticulocyte fraction, a tool that reflects erythroid engraftment and therefore marrow recovery and may be the earliest indicator of marrow recovery, preceded ANC recovery in ASCT by 3–6 days [7,8].

Neutrophil repopulation is an essential milestone in the post-transplant period as the nadir period signifies a vulnerability of the immune system to infection. Our case supports the developing notion that engraftment in ASCT indeed occurs earlier than our current understanding that is based on monitoring ANC. The implications of confirming earlier engraftment in clinical practice may lead to shorter hospital durations, more judicious use of antimicrobial therapy, and perhaps a shift in investigating patients with late onset febrile neutropenia in the posttransplant period. Novel tools of predicting marrow recovery may be combined with the existing method of ANC monitoring or may serve as a stand-alone tool, however further randomized prospective clinical trials would be needed before a tangible change in clinical practice can occur. Furthermore, findings involving autologous stem cell rescue such as this case may not be generalizable to allogenic stem cell transplants.

ACKNOWLEDGMENTS

The research reported in this manuscript was supported by the National Cancer Institute of the National Institutes of Health (NIH) under award number R37CA225791. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

INFORMED CONSENT

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available on request.

AUTHOR CONTRIBUTIONS

Bushra Tbakhi and Fateeha Furqan designed the research, interpreted the data, and wrote the paper. Glynis Scott contributed to data acquisition and interpretation. Jane L. Liesveld and Omar S. AlJitawi revised the manuscript critically for important intellectual content.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Bushra Tbakhi https://orcid.org/0000-0003-1717-9396

Fateeha Furqan https://orcid.org/0000-0001-7262-4953

REFERENCES

1. Ali M, Oyama Y, Monreal J, Winter J, Tallman M, Gordon LI, et al. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 \times 10^9/l neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant. 2002;30(11):749.
2. Abdelhalim H, Bhatti S, Cantilena AR, Lin TL, Ganguly S, Singh AK, et al. Hypophosphatemia (a drop in levels by 20%) is an electrolyte that can also reflect marrow recovery due to cell replication, although this is nonspecific and can be influenced by iatrogenic supplementation [7,9]. In this particular case, hypophosphatemia, specifically a drop of 47% from baseline occurred congruently with the evidence of tissue neutrophil delivery, monocyte recovery, and prior to ANC recovery. Immature reticulocyte fraction, a tool that reflects erythroid engraftment and therefore marrow recovery and may be the earliest indicator of marrow recovery, preceded ANC recovery in ASCT by 3–6 days [7,8].
3. Furze RC, Rankin SM. Neutrophil mobilization and recovery: it is not necessary to see 0.5 \times 10^9/l neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant. 2002;30(11):749.
4. Abdelhalim H, Shune L, Bhatti S, Cantilena AR, Baran A, Lin TL, et al. Outcomes of autologous hematopoietic cell transplantation patients receiving hyperbaric oxygen therapy. Biol Blood Marrow Transplant. 2017;23(3):S131-2.
5. Wilcox ME, Charbonney E, d’Empaire PP, Duggal A, Pinto R, Javid A, et al. Oral neutrophils are an independent marker of the systemic inflammatory response after cardiac bypass. J Inflamm. 2014;11(1):32.
6. Wilcox ME, Charbonney E, d’Empaire PP, Duggal A, Pinto R, Javid A, et al. Oral neutrophils are an independent marker of the systemic inflammatory response after cardiac bypass. J Inflamm. 2014;11(1):32.
6. Pink R, Vondrakova J, Tvrdy P, Michl P, Pazdera J, Faber E, et al. Salivary neutrophils level as an indicator of bone marrow engraftment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009;153(4):263-9.

7. Grazziutti ML, Dong L, Miceli MH, Cottler-Fox M, Krishna SG, Fassas A, et al. Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplant. 2006;37(4):403-9.

8. Noronha JFA, De Souza CA, Vigorito AC, Aranha FJP, Zulli R, Miranda ECM, et al. Immature reticulocytes as an early predictor of engraftment in autologous and allogeneic bone marrow transplantation. Clin. Lab. Haematol. 2003;25(1):47-54.

9. Raanani P, Levi I, Holzman F, Grotto I, Brok-Simoni F, Avigdor A, et al. Engraftment-associated hypophosphatemia–the role of cytokine release and steep leukocyte rise post stem cell transplantation. Bone Marrow Transplant. 2001;27(3):311.

10. Forster C, Aboodi G, Lipton J, Glogauer M. A non-invasive oral rinse assay predicts bone marrow engraftment and 6 months prognosis following allogeneic hematopoietic stem cell transplantation. J Oral Pathol Med. 2012;41(2):165-70.

11. Cheretakis C, Dror Y, Glogauer M. A noninvasive oral rinse assay to monitor engraftment, neutrophil tissue delivery and susceptibility to infection following HSCT in pediatric patients. Bone Marrow Transplant. 2005;36(3):227-32.

12. Kahng J, Yahng S-A, Lee JW, Kim Y, Kim M, Oh E-J, et al. Novel markers of early neutrophilic and monocytic engraftment after hematopoietic stem cell transplantation. Ann Lab Med. 2014;34(2):92-7.

How to cite this article: Tbakhi B, Furqan F, Scott G, Liesveld JL, Aljitawi OS. Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report. eJHaem. 2020;1:330–333.
https://doi.org/10.1002/jha2.65